Eupraxia Pharmaceuticals Insider Trading

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company focused on developing products for therapeutic areas with unmet medical need. The company uses its proprietary Diffusphere technology to optimize drug delivery across applications where significant unmet medical need exists. Its product portfolio consists of three candidates. EP-104IAR is currently in a Phase III clinical trial for the treatment of knee osteoarthritis. EP-104GI is in a Phase II clinical trial for the treatment of eosinophilic esophagitis. EP-104 is in preclinical studies targeting gastrointestinal conditions, including eosinophilic esophagitis. The company was previously named Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. It was incorporated in 2011 and is headquartered in Victoria, Canada. Eupraxia operates within the healthcare sector, specifically in the biotechnology industry. The company’s work centers on advancing drug delivery solutions through its pipeline of clinical and preclinical programs aimed at conditions where existing treatment options remain limited or insufficient.